Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
confirmed today that interim data from the companys Phase IB expansion
study (PN 001) evaluating the efficacy and safety of *MK-3475 in
patients with refractory non-small cell lung cancer (NSCLC) is scheduled
for presentation at the 15th
World Conference on Lung Cancer on Oct. 29 at 4:15 p.m., (1:15 a.m.
EDT), in Sydney, Australia.
Language:
English
Contact:
MerckMedia:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more